Volume 15 Number 1
31 January 2015

Home > Publications > Current Neuro-Oncology > Volume 17, Year 2015 > Number 1, 31 January

Mallidi S, Watanabe K, Timerman D, Schoenfeld D, Hasan T.
Prediction of tumor recurrence and therapy monitoring using ultrasound-guided photoacoustic imaging.
Theranostics. 2015 Jan 1;5(3):289-301. doi: 10.7150/thno.10155🡥. PMID: 25553116🡥. Laboratory investigation. ˍ

Jia PF, Gu WT, Zhang WF, Li F.
Treatment of recurrent malignant gliomas with 13-cis-retinoic acid naphthalene triazole.
Neurol Sci. 2015 Jan 6, 2015;36(5):717-21. doi: 10.1007/s10072-014-2025-9🡥. PMID: 25560534🡥. Clinical trial. ˍ

Chamberlain MC.
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
J Neurooncol. 2015 Jan 7, 2015;122(2):329-38. doi: 10.1007/s11060-014-1714-9🡥. PMID: 25563816🡥. Retrospective analysis. ˍ

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY.
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Neuro Oncol. 2015 Jan 7, 2015;17(6):862-7. doi: 10.1093/neuonc/nou350🡥. PMID: 25572329🡥. Phase 2 trial. ˍ
Neuro Oncol. 2015 Sep 19. 2015;17(12):1650. doi: 10.1093/neuonc/nov201🡥. PMID: 26386410🡥. Correction. ˍ

Duerinck J, Clement PM, Bouttens F, Andre C, Neyns B, Staelens Y, Van Fraeyenhove F, Baurain JF, Luce S, D'hondt L, Joosens E, Specenier P, Verschaeve V, Filleul B, Vroman P, Stragier B, Rogiers A.
Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma.
J Neurol. 2015 Jan 9, 2015;262(3):742-51. doi: 10.1007/s00415-014-7633-z🡥. PMID: 25572162🡥. Clinical trial. ˍ

Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Ozcelik M, Esenkaya A, Saygi HM, Uzunoglu S, Cicin I.
Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Med Oncol. 2015 Jan 9, 2015;32(2):460. doi: 10.1007/s12032-014-0460-3🡥. PMID: 25572814🡥. Retrospective analysis. ˍ
Med Oncol. 2015 Mar 19. 2015;32(4):119. doi: 10.1007/s12032-015-0482-5🡥. PMID: 25782869🡥. Correction. ˍ

Levin VA, Mendelssohn ND, Chan J, Stovall MC, Peak SJ, Yee JL, Hui RL, Chen DM.
Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
J Neurooncol. 2015 Jan 11, 2015;122(1):145-50. doi: 10.1007/s11060-014-1693-x🡥. PMID: 25575937🡥. Retrospective analysis. ˍ

Yordanova YN, Rodriguez-Arribas MA, Duffau H.
Long-term stabilization by radiosurgery of a secondary focal anaplastic transformation in a surgically treated WHO grade II oligodendroglioma. A case report.
Neurochirurgie. 2015 Jan 13, 2015;61(1):46-9. doi: 10.1016/j.neuchi.2014.11.006
🡥. PMID: 25595594🡥. Case report. ˍ

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.
Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
J Neurosurg. 2015 Jan 16, 2015;122(4):757-65. doi: 10.3171/2014.11.JNS13295🡥. PMID: 25594327🡥. Retrospective analysis. ˍ

Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J, Hausman DF, Mason WP.
Phase II study of PX-866 in recurrent glioblastoma.
Neuro Oncol. 2015 Jan 20, 2015;17(9):1270-4. doi: 10.1093/neuonc/nou365🡥. PMID: 25605819🡥. Phase 2 trial. ˍ

Wong ET, Lok E, Swanson KD.
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Cancer Med. 2015 Jan 26, 2015;4(3):383-91. doi:
10.1002/cam4.421🡥. PMID: 25620708🡥. Retrospective analysis. ˍ

Chen W, Wang D, Du X, He Y, Chen S, Shao Q, Ma C, Huang B, Chen A, Zhao P, Qu X, Li X.
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Med Oncol. 2015 Jan 29, 2015;32(3):43
🡥. doi: 10.1007/s12032-015-0487-0🡥. PMID: 25631631🡥. Laboratory investigation. ˍ
Erratum in: Med Oncol. 2021 Aug 24;38(10):117🡥. Correction. ˍ